Expert Interview
Discussing the potential of domvanalimab, the first Fc-silent anti-TIGIT monoclonal antibody, and the results from the ARC-7 study of domvanalimab as first-line treatment in metastatic NSCLC presented at the 2023 ASCO meeting
Ticker(s): GILDInstitution: UH Seidman Cancer Center
- · Manages 60 patients with NSCLC
- · Prescribed Lumakras to 4 patients so far
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
